July 10, 2018



CV Sciences, Inc. to Host Annual Meeting of Shareholders and Investor Day on August 4, 2018 in San Diego, California

Company to Feature Guest Speaker, World-Renowned Neurosurgeon and Sports Medicine Expert Dr. Joseph Maroon

LAS VEGAS, July 10, 2018 (GLOBE NEWSWIRE) -- <u>CV Sciences, Inc.</u> (OTCQB:CVSI) (the "Company," "CV Sciences," "our" or "we") will hold its annual meeting of shareholders (AGM) and Investor Day on Saturday, August 4, 2018, at the Company's corporate office located at 10070 Barnes Canyon Rd., Suite 100, San Diego, CA 92121. On-site registration begins at 9 a.m. PDT, and the meeting will begin at 10 a.m. PDT.

The event will begin with the Company's AGM, which will include: the election of four directors to serve until the Company's 2019 AGM, ratification of Tanner as the Company's independent registered public accounting firm for fiscal year 2018, amendment of the Company's amended and restated 2013 Equity Incentive Plan, and an amendment to the Company's certificate of incorporation at the discretion of the board of directors to effect a reverse stock split of all outstanding shares of the Company's common stock without further authorization of stockholders.

The Investor Day will feature a corporate presentation from the Company's senior management team who will overview the Company's business strategy and highlights of its recent (record) earnings quarter, followed by a tour of its new facility.

The Company also welcomes guest speaker, world-renowned neurosurgeon and sports medicine expert, Dr. Joseph C. Maroon, who will speak about the health and nutrition industry and natural alternatives in treating chronic injuries sustained by physical activities primarily in the sports field. In addition, his discussion will highlight his personal interest in healthy living and nutrition and his views on the effectiveness of hemp and CBD in various treatments.

Dr. Maroon obtained his medical and neurosurgical training at Indiana University, Georgetown University, Oxford University in England and the University of Vermont. He conducted extensive research into neurotrauma, brain tumors and diseases of the spine, which has led to many innovative techniques for diagnosing and treating these disorders. His research efforts garnered him numerous awards from various national and international neurological societies.

Attendance is by invitation only as space for the event is limited. Institutional investors, financial analysts, and media interested in attending are encouraged to contact Investor Relations at ir@cvsciences.com.

About CV Sciences, Inc.

CV Sciences, Inc. (OTCQB:CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and a consumer product division focused on manufacturing, marketing and selling plant-based CBD products to a range of market sectors. CV Sciences, Inc. has primary offices and facilities in Las Vegas, Nevada, and San Diego, California. Additional information is available from <u>OTCMarkets.com</u> or by visiting <u>www.cvsciences.com</u>.

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.

CONTACT INFORMATION:

Robert Haag

Managing Director

IRTH Communications

CVSI@irthcommunications.com

866-976-4784



Source: CV Sciences, Inc.